loading...| Preferred Name |
tinzaparin sodium |
|
| Synonyms |
Innohep |
|
| Definitions |
The sodium salt of a low molecular weight heparin (LMWH) obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60810" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60810" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000467737 |
|
| altLabel |
Innohep |
|
| cui |
C0354599 C0591649 |
|
| DATE FIRST PUBLISHED |
2006-02-21 |
|
| Date last modified |
2006-11-07 |
|
| definition |
The sodium salt of a low molecular weight heparin (LMWH) obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60810" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60810" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C60810 |
|
| notation |
CDR0000467737 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
tinzaparin sodium |
|
| tui |
T109 T121 |